April 14th, 2011 -- Immune Response BioPharma Launches First Strike on MS Treatment Costs, Sees NeuroVax Initial Pricing at $500 per Dose a 75% Cost Reduction for MS Patients Saving Health Insurers and Patients Billions of Dollars NeuroVax First in Class Best in Class MS Treatment. Catalent is the likely Manufacturer for NeuroVax, and Either CRO Covance or PRA International will Handle Clinical Trials.
Immune Response BioPharma, Fredericksburg, Virginia Today 4/14/2011 privately held, Sees initial pricing for NeuroVax around $500 per dose a once a month treatment for MS patients saving them and health insurers up to 75% in direct costs a real savings to both patients and health insurers. NeuroVax is a more safer and tolerable treatment that will help bring MS patients therapeutic and cost benefits. IRBP has had fruitful discussions with Catalent about manufacturing the NeuroVax vaccine and that looks promising. Raising capital for the project will be the key issue the company faces going forward to fund the trial costs.
IRBP has been engaged by two CRO’s Covance and PRA International about handling clinical trials for NeuroVax when the company reaches that milestone. Assuming the FDA allows the company to pick up where NeuroVax left off with a 200 patient dose ranging trial the company will be very pleased to help bring this important treatment to the millions of MS patients who suffer from this awful disease. IRBP estimates around 2015 range would be a likely timeframe for completing all clinical trials, IRBP hopes to complete necessary clinical trials and move towards a NDA filing with the FDA by late 2015 range for putting NeuroVax up to a vote by the FDA, at earliest it would be sometime in 2016 before patients could receive the NeuroVax treatment. IRBP estimates an immediate 10% market share for MS treatments upon FDA approval in 2016 range.
“NeuroVax is a first in class best in class treatment for MS which Dr. Joesph O’neill a great man of medicine had acknowledged to me there was nothing wrong with the vaccine which I knew was the case, all along it was a funding issue which derailed the efforts of bringing this important vaccine to MS patients. Hopefully funding is secured and I can bring aboard world class doctors and scientists to help me get NeuroVax through the clinical trials process and into doctors and patients hands” Mr. Buswell Chief Operating Officer.
“Now the big challenge of raising capital for the clinical trials, I am in the process of building a world class BioPharmaceutical company, a lot of work is yet to be done, incorporating and raising cash to fund the trials. I am confident that a world class treatment for MS will bring funding on favorable terms” Mr. Buswell Chief Operating Officer.
“I am disappointed in Mr. Gates and the Gates Foundation as they turned down an opportunity to help fund NeuroVax, this is contrary to the message Mr.Gates put out on television and his comments, and unfortunately he doesn’t put his money where his mouth is. I don’t need Gates money but MS patients should know he turned down my grant request, very sad and unfortunate that Gates refuses to help MS patients. I encourage those who have the ability to help fund important drugs like NeuroVax to step up to the plate and do the right thing and help secure funding” Mr.Buswell COO IRBP.
